Evaluation of the Efficacy of Management of Patients With Lymphomas Diagnosed at Nimes University Hospital Over 20 Years (1999-2018) Under Real-life Circumstances
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 136
- 试验地点
- 3
- 主要终点
- Overall survival rate among patients with Waldenström's Disease
研究概览
简要总结
Observation of a cohort of 400 patients with different types of lymphomas.
详细描述
A database on 400 patients diagnosed with lymphomas was built up over 20 years at Nîmes University Hospital. Biopsies were made on these tumours and all the samples were frozen.
Considering the heterogeneous nature of lymphomas, randomized clinical trials based on very precise criteria for the inclusion or non-inclusion of patients are the gold standard for studying the various sub-types of lymphomas by concentrating on homogeneous populations for which a limited number of parameters are analyzed simultaneously. However, due to the complexity of their medical situation, many patients may be excluded form these trials, thus making it difficult to obtain reliable results.
The analysis of a non-selected cohort has two main advantages: (1) to better understand the diversity of patients with lymphomas for which the recommendations are constantly evolving and (2) to analyze how, exactly, these are managed by integrating points which are currently poorly evaluated such as comorbidities and accessibility to treatment.
The aim of the study is to describe how these patients are managed and to demonstrate that not all patients are able to benefit from the official management recommendations applicable to their pathology.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients over the age of 15 years and 3 months, diagnosed with lymphoma at Nîmes University Hospital as from 1999 onwards and for whom diagnostic tumor material is available.
排除标准
- •Patients aged 18 or over who have expressed their desire not to take part in the study.
- •Patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study.
- •Patients under legal guardianship.
结局指标
主要结局
Overall survival rate among patients with Waldenström's Disease
时间窗: 2 years after inclusion
If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Follicular Lymphomas
时间窗: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Mantle-cell Lymphomas
时间窗: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted.If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Primitive Cerebral Lymphomas
时间窗: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Marginal Zone Lymphomas
时间窗: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Hodgkin Lymphomas
时间窗: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
次要结局
- Differences between management of patients with Mantle-cell Lymphomas and data described in the literature.(2 years after inclusion)
- Differences between management of patients with Marginal Zone Lymphomas and data described in the literature.(2 years after inclusion)
- Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.(2 years after inclusion)
- Differences between management of patients with Waldenström's Disease and data described in the literature.(2 years after inclusion)
- Reasons for differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.(2 years after inclusion)
- Analysis of the efficacy of treatment of patients with Waldenström's Disease(2 years after inclusion)
- Analysis of the efficacy of treatment of patients with Follicular Lymphomas(2 years after inclusion)
- Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature.(2 years after inclusion)
- Differences between management of patients with Follicular Lymphomas and data described in the literature.(2 years after inclusion)
- Reasons for differences between management of patients with Waldenström's Disease actually observed and data described in the literature.(2 years after inclusion)
- Analysis of the efficacy of treatment of patients with Mantle-cell Lymphomas(2 years after inclusion)
- Reasons for differences between management of patients with Mantle-cell Lymphomas actually observed and data described in the literature.(2 years after inclusion)
- Reasons for differences between management of patients with Follicular Lymphomas actually observed and data described in the literature.(2 years after inclusion)
- Analysis of the efficacy of treatment of patients with Hodgkin Lymphomas.(2 years after inclusion)
- Reasons for differences between management of patients with Primitive Cerebral Lymphomas actually observed and data described in the literature.(2 years after inclusion)
- Reasons for differences between management of patients with Marginal Zone Lymphomas actually observed and data described in the literature.(2 years after inclusion)
- Analysis of the efficacy of treatment of patients with Primitive Cerebral Lymphomas(2 years after inclusion)
- Analysis of the efficacy of treatment of patients with Marginal Zone Lymphomas(2 years after inclusion)